Clopidogrel

證據等級: L5

預測適應症: 8 個

Clopidogrel: Drug Repurposing Evaluation — No Predictions Available

One-Sentence Summary

Clopidogrel (DrugBank ID: DB00758) is a pharmaceutical compound submitted for drug repurposing evaluation in this cycle. However, the TxGNN model did not generate any predicted new indications, and critical data items — including mechanism of action, original indication, and safety information — are currently unavailable. This report documents the data gaps and outlines the steps required before a substantive evaluation can proceed.

Quick Overview

Item	Content
Original Indication	Not available in current dataset
Predicted New Indication	No prediction generated
TxGNN Prediction Score	N/A
Evidence Level	L5 — Model prediction not generated; evaluation cannot proceed
Italy Market Status	Not marketed (per current dataset)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No mechanism of action data is available for this evaluation cycle. The original_moa field was not populated, and although the DrugBank query returned one result, the MOA content was not extracted into the Evidence Pack.

Because predicted_indications is empty, the TxGNN model did not produce any repurposing candidates for Clopidogrel in this run. Without a target indication, it is not possible to assess mechanistic plausibility or the relationship between original and new uses.

Additionally, the original indications list is empty, which prevents a baseline characterisation of what therapeutic area the drug currently addresses.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Italy Market Information

No regulatory authorizations found in the current dataset. The queried Italy market status returned zero licenses.

Note: The TFDA/AIFA package insert query log shows a successful result (result_count: 1), but the contents were not parsed into the Evidence Pack. Italy registration data may exist and should be retrieved in the next data collection cycle.

Safety Considerations

Please refer to the package insert for safety information.

The package insert query returned a successful result but was not parsed into structured safety fields. Key warnings, contraindications, and drug interaction data remain unavailable.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack for Clopidogrel is incomplete at a foundational level — no TxGNN predictions were generated and all drug-level data fields are empty or unpopulated. A repurposing evaluation cannot be meaningfully conducted under these conditions.

To proceed, the following is needed:

Re-run TxGNN prediction pipeline for DB00758 to generate predicted_indications with scores, clinical trial links, and literature references
Extract MOA from DrugBank — the DrugBank query returned 1 successful result; the mechanism of action should be parsed and populated (Data Gap DG002)
Parse package insert for safety data — the TFDA package insert query returned 1 successful result; key warnings and contraindications should be extracted (Data Gap DG001)
Verify Italy/AIFA market status — Clopidogrel is a widely distributed antiplatelet agent; the current 0-license result likely reflects a data pipeline gap rather than actual market absence
Populate original indications — the original_indications field is empty and must be filled before any from/to repurposing framing is possible
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.